Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5825-5831

  Sadar, M D ^a   Gleave, M E ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; BUTYRIC ACID; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; TRANSCRIPTION INITIATION;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; BUTYRATES; CELL DIFFERENTIATION; CELL NUCLEUS; DRUG INTERACTIONS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0034667457     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Structural determinants of DNA-binding specificity by steroid receptors
2. Localization of functional domains in the androgen receptor
3. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation
4. AR activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
5. Activation of the human androgen receptor through a protein kinase A signaling pathway
6. Androgen-independent induction of prostate specific antigen gene expression via cross-talk between the androgen receptor and PKA signal transduction pathways
7. Molecular biology of tissue kallikrein
8. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
9. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
10. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
11. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
12. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model
13. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells
14. Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP prostate cancer cells
15. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells
16. 3 actions in LNCaP human prostate cancer cells are androgen-dependent
17. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
18. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: Comparative analyses of MDA PCa2a with established cell lines
19. Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell
20. Effects of sodium butyrate, a new pharmacological agent, on cells in culture
21. Molecular analysis of sodium butyrate-induced growth arrest
22. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function
23. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells
24. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells
25. Cellular protein synthesis and inhibition of cell division are independent of butyrate-induced histone hyperacetylation
26. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate
27. The effect of sodium butyrate on histone modification
28. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line
29. Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT-29 colonic epithelial cells
30. Sodium butyrate inhibits the phosphorylation of the retinoblastoma gene product in mouse fibroblasts by a transcription-dependent mechanism
31. The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase
32. Morphological and biochemical differentiation in HeLa cells. Effects of cycloheximide on butyrate-induced process formation and ganglioside metabolism
33. Depletion of sodium butyrate from the culture medium of Friend erythroleukemia cells undergoing differentiation
34. Butyrate synchronization of hepatocytes: Modulation of cycling and cell cycle regulated gene expression
35. Effect of sodium butyrate on the hepatoma cell cycle: Possible use for cell synchronization
36. Prostate-specific antigen expression is regulated by an upstream enhancer
37. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP
38. Differential transactivation by the androgen receptor in prostate cancer cells
39. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
40. Rapid detection of octamer binding proteins with 'mini-extracts' prepared from a small number of cells
41. Adipsin gene expression in 3T3-F442A adipocytes is posttranscriptionally down-regulated by retinoic acid
42. Prostate-specific antigen expression is regulated by an upstream enhancer
43. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides
44. Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: Use of a new monoclonal antibody to distinguish transformed from nontransformed receptors
45. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
46. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors
47. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 β action
48. Progesterone receptor regulation in uterine cells: Stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors
49. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I
50. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element
51. The unliganded estrogen receptor (ER) transduces growth factor signals
52. Activation of the progesterone receptor by the gonadotropin-releasing hormone self-priming signaling pathway
53. Modulation of human mineralocorticoid receptor function by protein kinase A
54. Tumor-promoting phorbol ester-induced cell death and gene expression in a human prostate adenocarcinoma cell line
55. 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase